California-Based Pharma Co.'s Progress Offers Upside
Source: Dr. Swayampakula Ramakanth  (1/2/24)
While H.C. Wainwright & Co. lowered their price target, they still see upside for this pharmaceutical company. More >

Contracts Add Thousands of Patients to Telehealth Platform
  (12/28/23)
Reliq Health Technologies Inc. says it has signed new contracts with 10 physician practices in three states to add thousands more patients to its iUGO telehealth platform. More >

Co.'s Breast Cancer Therapy Shows Encouraging Activity
Source: Emily Bodnar  (12/28/23)
BriaCell Therapeutics Corp.'s lead targeted cell therapy, when combined with the PD-1 inhibitor retifanlimab, achieved an exceptional 71% intracranial objective response rate treating brain metastases in advanced breast cancer patients, according to an H.C. Wainwright report. More >

Biotech Secures Additional Funding, Extending Cash Runway
Source: Ed Arce  (12/27/23)
Recently, Vera Therapeutics Inc. announced it had further strengthened its balance sheet by drawing down US$25 million in debt, bringing total cash reserves to US$159.9 million, noted H.C. Wainwright & Co. More >

Biotech Bolsters ADC Pipeline Through Atreca Asset Buy
Source: Dr. David Nierengarten  (12/26/23)
Biotech Immunome Inc. recently announced a purchase agreement with Altreca, noted Wedbush. More >

US Biotech's Anti-Fungal Wins European Approvals
Source: Ed Arce  (12/22/23)
Recently, Cidara Therapeutics Inc. secured European Commission (EC) approval for its lead anti-fungal candidate Rezafungin to treat invasive candidiasis infections in adults, noted H.C. Wainwright & Co. More >

Biotech Co. Reports Encouraging ALS Data but FDA Wants More
Source: Dr. Jonathan Aschoff  (12/21/23)
Salt Lake City-based Clene Inc. reported both encouraging clinical data and a regulatory setback for its ALS drug candidate CNM-Au8, reported Roth MKM. More >

Pharma Co. May Have Accelerated FDA Approval in 2024
Source: Edward White  (12/20/23)
TRACON Pharmaceuticals Inc. provided an update on enrollment progress for their ongoing Phase 2 ENVASARC clinical trial testing the drug envafolimab to treat sarcoma, reported H.C. Wainwright & Co. More >

Lithium Co. Will Be a Substantial Outperformer
Source: Michael Ballanger  (12/19/23)
Michael Ballanger of GGM Advisory Inc. shares a quick note about why he has faith in Volt Lithium Corp. More >

Bioscience Co. Expands Collaboration
Source: Dr. Jonathan Aschoff  (12/19/23)
This bioscience company's price target implies 680% upside, according to a Roth MKM report. More >

Promising Biotech Selling Way Under Cash Value
Source: Ron Struthers  (12/18/23)
Nkarta is using CRISPR technology for cell therapies for leukemia. The FDA just approved a similar cell therapy treatment for Vertex using the same CRISPR technology. Nkarta is trading well below cash value and has a significant short position sinking underwater. More >

Texas Biotech Advances Lead Candidate in Resistant AML
Source: Dr. Jonathan Aschoff  (12/14/23)
Recently, Texas-based biotech Bio-Path Holdings Inc. announced it had completed the first safety cohort of a Phase 1/1b trial evaluating the developmental drug BP1002 in acute myeloid leukemia (AML). Read on to see what one Roth analyst has to say about the company's stock. More >

Biotech Seeks Approval of Synthetic Blood Vessel Graft
Source: Vernon Bernardino  (12/12/23)
Humacyte Inc. announced the submission of a Biologics License Application (BLA) to the FDA seeking approval for its lead product candidate Human Acellular Vessel (HAV), noted H.C. Wainwright & Co. Analyst Vernon Bernardino. More >

Drugs Show Anti-Cancer Effects on Myeloma Cells
Source: Dr. Jonathan Aschoff  (12/6/23)
These positive results bode well for the biopharma's two polyamine inhibitors as potential treatments for multiple myeloma, noted a ROTH Capital Markets report. More >

Antibodies from Vaccine Remain Two Years Out
Source: Edward White  (12/6/23)
This was shown in recent clinical trial results of a biotech's single-dose vaccine against chikungunya evaluated in adults, noted an H.C. Wainwright & Co. report. More >

Pharma Co. Reports Positive Data for Leukemia Combination Therapy
Source: Andrew Fein  (12/6/23)
Recently, Syros Pharmaceuticals Inc. announced positive data for its Leukemia Combination Therapy, noted an H.C. Wainwright & Co. report. More >

Massachusetts Biotech Plummets as Skin Cancer Trial Fails
Source: Streetwise Reports  (12/5/23)
In recent news, Massachusetts clinical-stage biotechnology company Replimune Group Inc. revealed its latest clinical trial did not meet the endpoints needed to call it a success. With this, the stock has plummeted. More >

Pharma Co.'s Partnership a Key Validation
Source: Dr. Robert Driscoll  (12/4/23)
Recently, Arcus Biosciences Inc. announced a partnership with Exelixis Inc., which may be the key to validating the company, noted WedBush analysts in a December 4 report. More >

Biotech Announces New Responder in Breast Cancer Trail
Source: Emily Bodnar  (11/30/23)
Recently, BriaCell Therapeutics Corp. announced a new exceptional responder in its Phase 2 study evaluating the company's off-the-shelf personalized immunotherapy, noted H.C. Wainwright analyst Emily Bodnar. More >

Biotech Receives First Approval; Drug Now Available
Source: Robert Burns  (11/28/23)
Recently, SpringWorks Therapeutics Inc. announced FDA approval of OGSIVEO (nirogacestat) for treating progressing desmoid tumors (DT) in adult patients based on Phase 3 DeFi trial results, noted H.C. Wainwright & Co. analysts Robert Burns and Dr. Raghuram Selvaraju. More >

Encouraging Early Data For Biotech's Cancer Therapies
Source: Emily Bodnar  (11/21/23)
In a recent corporate update, Purple Biotech Ltd. reported positive interim Phase 1/2 data for NT219 and accelerated enrollment for CM24, noted H.C. Wainwright analyst Emily Bodnar. More >

Strong Early Launch Metrics for Biotech's Skin Disease Drug
Source: Oren Livnat  (11/20/23)
Oren Livnat of H.C. Wainwright & Co. sees over 240% upside potential for Verrica Pharmaceuticals based on the early commercial success of its recently launched skin disease treatment. More >

Arizona Biotech Advances Multiple Cell Therapies
Source: Dr. Jonathan Aschoff  (11/16/23)
Roth MKM has a US$30 price target on this biotech company based on progress across its regenerative medicine pipeline, including upcoming Phase 1/2 data. More >

Massachusetts Biotech Advances Novel Cytokine Therapies
Source: Dr. Robert Driscoll  (11/15/23)
Wedbush sees over 300% upside for Werewolf stock based on early clinical success for its PREDATOR platform and pipeline, according to a WedBush research note. More >

Massachusetts Biotech Presents Catalysts Into 2024
Source: Dr. David Nierengarten  (11/8/23)
Cambridge, Massachusetts-based iTeos Therapeutics presented multiple upcoming catalysts into 2024 after reporting Q3 results, noted Wedbush analyst Dr. David Nierengarten. More >